The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males

The maximum drug concentration (Cmax) of CDP6038 in plasma given by intravenous (iv) infusion and subcutaneous (sc) injection in healthy male subjects.

Time frame: Baseline to 14 weeks

The area under the plasma concentration/time curve from hour 0 to the time with the last quantifiable level of CDP6038 given by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks

The area under the plasma concentration/time curve extrapolated to infinity, of CDP6038 given by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks

The half life of CDP6038 in plasma given by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks

The apparent volume of distribution of CDP6038 given by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks

Total body clearance of CDP6038 in plasma given by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks

PK/PD relationship between systemic CDP6038 exposure and suppression of selected acute phase markers (such as C-reactive protein) following CDP6038 administration by iv infusion and sc injection in healthy male subjects.

Time frame: Baseline to 14 weeks